Proteon Therapeutics
Developing pharmaceuticals for patients with renal and vascular diseases.
HQ location
Waltham, United States
Website
Launch date
Enterprise value
$180—270m
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
€21.0m | Post IPO Equity | ||
| Total Funding | 000k | ||
TVM Capital Life Science(exited)
Bessemer Venture Partners(exited)
MPM BioImpact(exited)
Intersouth Partners(exited)
Abingworth(exited)
Deerfield Partners(exited)
Skyline Ventures(exited)
Inbio Ventures(exited)
Devon Park BioVentures(exited)
Pharmstandard(exited)
Prism Venture Management(exited)
Vectis Capital(exited)
Omega Funds(exited)
Deerfield(exited)
European Commission(exited)
| USD | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | 600 % | - |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| % profit margin | (2100 %) | (443 %) | - |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.